open access

Vol 5, No 4 (2001)
Prace oryginalne
Published online: 2001-10-03
Get Citation

Efficacy and Acceptability of the Indapamide SR 1,5 mg (Tertensif ® SR) in Patients above 55 Years of Age with Isolated Systolic Hypertension - the STIP Study

Walerian Piotrowski, Piotr Włodarczyk, Bogdan Jasiński, Stefan Rywik
Nadciśnienie tętnicze 2001;5(4):245-254.

open access

Vol 5, No 4 (2001)
Prace oryginalne
Published online: 2001-10-03

Abstract

Background Isolated systolic hypertension is a significant health problem for Polish society.Modified release forms of available drugs are becoming the treatments of choice. The aim of the presented work was to evaluate the efficacy and tolerance of a sustained release form of indapamide at a dose of 1,5 mg (Tertensif ® SR)in the treatment of patients above 55 years of age,with mild to moderate isolated systolic hypertension.
Materials and methods The study was a multi-centre study in Polish health centres.Patients were recruited into the study from those taking part in the WISHE-Poland programme,where isolated systolic hypertension was diagnosed i.e:the average SBP pressure was in the range of 140 –179 mm Hg and DBP <90 mm Hg.Treatment was carried out for 12 weeks,during which time the patient attended 2 assessment visits,after 6 and 12 weeks.During the first 6 weeks patients received indapamide SR at a dose of 1,5 mg as a monotherapy.Patients who recorded a systolic pressure of 160 –179 mm Hg at week 6,were also given perindopril at a daily dose of 4 mg.After 12 weeks the investigator assessed the efficacy and tolerance of the treat- ment,in addition the patient was also asked to give their opinion on the tolerance.
Results The study was carried out in 570 patients between 56 –94 years of age (average age 67,5),61%of the patients were female.The mean baseline SBP/DBP value was 160/82 mm Hg.After 12 weeks of treatment,the mean value was 137/77 mm Hg.The mean decrease in SBP was over 20 mm Hg and that of DBP — nearly 5 mm Hg.The reduction in SBP pressure of the studied group was 14% and that of DBP — 6%.Analysis of the efficacy of the study treatment in the whole group of patients who completed the study (525 patients)shows that a good response (decrease in SBP >20 mm Hg and DBP <90 mm Hg) together with a normalization of the arterial pressure was seen in 70%of patients.The mean value of the partnership coefficient at week six was 98%and that at week twelve 99%.Less than 5%of patients (26 patients) experienced adverse events.A relationship between adverse events and treatment with indapamide was observed in 21 patients (<4%).99%of the patients assessed tolerance as good or very good,the investigator assessed such tolerance in 99%of the pateints.
Conclusions 1,5 mg indapamide SR (Tertensif ® SR)when administered to patients aged over 55,with mild to moderate isolated systolic hypertension,successfully decreased systolic pressure and was very well tolerated.

Abstract

Background Isolated systolic hypertension is a significant health problem for Polish society.Modified release forms of available drugs are becoming the treatments of choice. The aim of the presented work was to evaluate the efficacy and tolerance of a sustained release form of indapamide at a dose of 1,5 mg (Tertensif ® SR)in the treatment of patients above 55 years of age,with mild to moderate isolated systolic hypertension.
Materials and methods The study was a multi-centre study in Polish health centres.Patients were recruited into the study from those taking part in the WISHE-Poland programme,where isolated systolic hypertension was diagnosed i.e:the average SBP pressure was in the range of 140 –179 mm Hg and DBP <90 mm Hg.Treatment was carried out for 12 weeks,during which time the patient attended 2 assessment visits,after 6 and 12 weeks.During the first 6 weeks patients received indapamide SR at a dose of 1,5 mg as a monotherapy.Patients who recorded a systolic pressure of 160 –179 mm Hg at week 6,were also given perindopril at a daily dose of 4 mg.After 12 weeks the investigator assessed the efficacy and tolerance of the treat- ment,in addition the patient was also asked to give their opinion on the tolerance.
Results The study was carried out in 570 patients between 56 –94 years of age (average age 67,5),61%of the patients were female.The mean baseline SBP/DBP value was 160/82 mm Hg.After 12 weeks of treatment,the mean value was 137/77 mm Hg.The mean decrease in SBP was over 20 mm Hg and that of DBP — nearly 5 mm Hg.The reduction in SBP pressure of the studied group was 14% and that of DBP — 6%.Analysis of the efficacy of the study treatment in the whole group of patients who completed the study (525 patients)shows that a good response (decrease in SBP >20 mm Hg and DBP <90 mm Hg) together with a normalization of the arterial pressure was seen in 70%of patients.The mean value of the partnership coefficient at week six was 98%and that at week twelve 99%.Less than 5%of patients (26 patients) experienced adverse events.A relationship between adverse events and treatment with indapamide was observed in 21 patients (<4%).99%of the patients assessed tolerance as good or very good,the investigator assessed such tolerance in 99%of the pateints.
Conclusions 1,5 mg indapamide SR (Tertensif ® SR)when administered to patients aged over 55,with mild to moderate isolated systolic hypertension,successfully decreased systolic pressure and was very well tolerated.
Get Citation

Keywords

isolated systolic hypertension; elderly population; indapamide sustained-release 1; 5 mg

About this article
Title

Efficacy and Acceptability of the Indapamide SR 1,5 mg (Tertensif ® SR) in Patients above 55 Years of Age with Isolated Systolic Hypertension - the STIP Study

Journal

Arterial Hypertension

Issue

Vol 5, No 4 (2001)

Pages

245-254

Published online

2001-10-03

Bibliographic record

Nadciśnienie tętnicze 2001;5(4):245-254.

Keywords

isolated systolic hypertension
elderly population
indapamide sustained-release 1
5 mg

Authors

Walerian Piotrowski
Piotr Włodarczyk
Bogdan Jasiński
Stefan Rywik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl